Aspire BioPharma Inc. (ASBP)
Aspire BioPharma Statistics
Share Statistics
Aspire BioPharma has 48.9M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 48.9M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 48.38K |
| FTD / Avg. Volume | 9.5% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is null. Aspire BioPharma's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Aspire BioPharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.09, with a Debt / Equity ratio of -0.82.
| Current Ratio | 0.09 |
| Quick Ratio | 0.09 |
| Debt / Equity | -0.82 |
| Debt / EBITDA | - |
| Debt / FCF | -4.78 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-179.54K |
| Employee Count | 2 |
| Asset Turnover | null |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 481 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.86, so Aspire BioPharma's price volatility has been higher than the market average.
| Beta | 0.86 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.87 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 25.01 |
| Average Volume (20 Days) | 509.46K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -358.59K |
| Net Income | -359.07K |
| EBITDA | 0 |
| EBIT | -358.59K |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
The company has 3.63K in cash and 1.27M in debt, giving a net cash position of -1.26M.
| Cash & Cash Equivalents | 3.63K |
| Total Debt | 1.27M |
| Net Cash | -1.26M |
| Retained Earnings | -2.78M |
| Total Assets | 147.99K |
| Working Capital | -1.54M |
Cash Flow
In the last 12 months, operating cash flow was -265.19K and capital expenditures 0, giving a free cash flow of -265.19K.
| Operating Cash Flow | -265.19K |
| Capital Expenditures | 0 |
| Free Cash Flow | -265.19K |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ASBP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for ASBP.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -288.51 |
| Piotroski F-Score | 2 |